Arnd Schwebig

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy

Kimberly Blackwell, Vladimir Semiglazov, Dmitriy Krasnozhon et al. · Annals of Oncology · 2015 · 81 citations · Full text

Medicine, Oncology, Pharmacology +16

Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics

Fritz Sörgel, Arnd Schwebig, Johann Holzmann et al. · BioDrugs · 2015 · 53 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Silica dust and lung cancer in the German stone, quarrying, and ceramics industries: results of a case-control study

Kurt Ulm, B Waschulzik, H. Ehnes et al. · Thorax · 1999 · 48 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study

Marco Matucci‐Cerinic, Yannick Allanore, Arthur Kavanaugh et al. · RMD Open · 2018 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte‐colony‐stimulating factor: safety, efficacy, and graft performance

P. S. A. Becker, Arnd Schwebig, Susanne Bräuninger et al. · Transfusion · 2016 · 32 citations · Full text

Medicine, Hematology, Cell Therapy +16